Heart Study Required For Amarin's Vascepa

The Food and Drug Administration determined that a study on the heart risks of Amarin Corp.'s (Nasdaq: AMRN) Vascepa must be completed before discussions to potentially expand approved uses of the very high triglycerides treatment. The stock price plunged $1.28 to close at $5.09.

Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here